Meeting
2018 Gastrointestinal Cancers Symposium
Everolimus and transarterial embolization (TAE) for hepatic metastasis in neuroendocrine tumors (NET).
Authors
Aman Chauhan
University of Kentucky, Lexington, KY
Aman Chauhan , Gray Magee , Millicent Horn , Riham Khouli , Heidi Weiss , Steven J Krohmer , Lowell Brian Anthony
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 485)
DOI
10.1200/JCO.2018.36.4_suppl.485
Abstract #
485
Poster Bd #
N9
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Outcomes of locoregional treatment for unifocal progression in widespread metastatic gastroenteropancreatic neuroendocrine tumors.
First Author: Taymeyah E. Al-Toubah
Poster
2014 Gastrointestinal Cancers Symposium
Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors.
First Author: Robert Lance Fine
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Pivotal phase III COMPOSE trial will compare 177Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors.
First Author: Thorvardur Ragnar Halfdanarson
Poster
2021 Gastrointestinal Cancers Symposium
Cost of treatment change among patients with neuroendocrine tumors (NET) treated originally with somatostatin analogs.
First Author: Bernard Tawfik